Work

Neurostimulation for Cognitive Enhancement in Alzheimer’s Disease (the NICE-AD study): A Randomized Clinical Trial

Year: 2021

Type: article

Abstract: New therapies for symptoms in Alzheimer’s disease (AD) are urgently needed. Prior studies suggest that transcranial direct current stimulation (tDCS), a noninvasive neuromodulatory method, may be a safe and potentially effective treatment, but conclusions have been limited by small-sample sizes and brief stimulation protocols. This double-blind randomized trial involving 100 older adults with mild-to-moderate AD examines effects of 6 months of at-home active tDCS or sham delivered over the dorsolateral prefrontal cortex. The primary outcome is global cognitive performance. Secondary outcomes include executive-control/spatial selective attention, functional neuroplasticity, depressive symptoms, quality of life and the durability of effects 3 months after the stimulation period. The results will provide evidence on the efficacy of multimonth at-home tDCS in the AD treatment. =Clinical trial identifier NCT 04404153 (Clinicaltrials.gov).

Source: Neurodegenerative Disease Management

DOI: 10.2217/nmt-2020-0061